cancer treatment

Cancer treatment has witnessed a revolutionary shift over the past few decades—from conventional, broadly targeted methods to highly specific, immune-driven approaches. At the center of this transformation lies a promising class of drugs like ISB 2001, a trispecific antibody currently in clinical trials for relapsed/refractory multiple myeloma. Understanding how ISB 2001 works requires a brief journey through […]